Patents by Inventor Jeffrey A. Leiby

Jeffrey A. Leiby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FLAVIN DERIVATIVES
    Publication number: 20120295903
    Abstract: The present invention relates novel flavin derivatives and other flavin derivatives, their use and compositions for use as riboswitch ligands and/or anti-infectives. The invention also provides method of making novel flavin derivatives.
    Type: Application
    Filed: June 30, 2010
    Publication date: November 22, 2012
    Inventors: Kenneth F. Blount, Philip D.G. Coish, Brian R. Dixon, Jayhyuk Myung, David Osterman, Phil Wickens, Stephanie Avola, Nick Baboulas, Angelica Bello, Judd Berman, Harpreet Kaur, David Moon, Vinh Pham, Andrew Roughton, Jeffrey Wilson, Jeffrey A. Leiby, Dennis Underwood, Paul Adrian Aristoff, Heinrich J. Schostarez, Robert A. Chrusciel, Thomas R. Belliotti, Bruce R. Evans, Frank C. Sciavolino, Manuel A. Navia
  • FLAVIN DERIVATIVES
    Publication number: 20120077781
    Abstract: The present invention relates novel flavin derivatives and other flavin derivatives, their use and compositions for use as riboswitch ligands and/or anti-infectives. The invention also provides method of making novel flavin derivatives.
    Type: Application
    Filed: August 11, 2009
    Publication date: March 29, 2012
    Inventors: Robert Gadwood, Harpreet Kaur, Kevin Kells, Jeffrey A. Leiby, David Moon, Vinh Pham, Philip D.G. Coish, Kenneth F. Blount, Brian R. Dixon, Jayhyuk Myung, David Osterman, Stephanie Avola, Nick Baboulas, Angelica Bello, Judd Berman, Bruce R. Evans, Tan Quach, Heinrich J. Schostarez, Frank C. Sciavolino, Dennis Underwood, Phil Wickens, Jeffrey Wilson, Justin Wu
  • Phenylsulfonamide-phenylethylamines useful as dopamine receptors
    Patent number: 6103766
    Abstract: Compounds of Formula I and their pharmaceutically acceptable salts having selective dopamine D3 receptor activity suitable for treating central nervous system disorders. Formula I: ##STR1## R.sub.1 is independently H or a C.sub.1 -C.sub.8 alkyl including isomeric forms thereof;R.sub.2 is H, C.sub.1 -C.sub.3 alkyl, a halogen, OCH.sub.3 , OCF.sub.3, CF.sub.3, CN, SCH.sub.3 or NHCOCH.sub.3 ; andR.sub.3 is H, C.sub.1 -C.sub.3 alkyl, a halogen, OCH.sub.3 , OCF.sub.3, CF.sub.3, CN, SCH.sub.3 or NHCOCH.sub.3.
    Type: Grant
    Filed: May 7, 1999
    Date of Patent: August 15, 2000
    Assignee: Pharmacia & Upjohn Company
    Inventors: Arthur Glenn Romero, Jeffrey A. Leiby
  • Aryl substituted bicyclic amines as selective dopamine D3 ligands
    Patent number: 6084130
    Abstract: Compounds and their pharmaceutically acceptable salts suitable for treating central nervous system disorders associated with the dopamine D3 receptor activity of structural Formula I: ##STR1##
    Type: Grant
    Filed: May 20, 1997
    Date of Patent: July 4, 2000
    Assignee: Pharmacia & Upjohn Company
    Inventors: Arthur Glenn Romero, William Harold Darlington, Jeffrey A. Leiby, Chiu-Hong Lin, Susanne R. Haadsma-Svensson, Kerry Anne Cleek
  • 2-aminoindans as selective dopamine D3 ligands
    Patent number: 5936000
    Abstract: Compounds and their pharmaceutically acceptable salts suitable for treating central nervous system disorders associated with the dopamine D3 receptor activity of Formula I: wherein R.sub.1 and R.sub.2 are independently H, C.sub.1-8 alkyl or C.sub.1-8 alkylAryl; X is CH.sub.2 R.sub.3 or NHSO.sub.2 R.sub.4 ; Y is hydrogen, CH.sub.2 R.sub.3, NHSO.sub.2 R.sub.4, CONR.sub.1 R.sub.2, SO.sub.2 NR.sub.1 R.sub.2, SO.sub.2 CH.sub.3, halogen, OSO.sub.2 CF.sub.3, SCH.sub.3 or OCH.sub.3 ; R.sub.3 is NHSO.sub.2 R.sub.4, SO.sub.2 R.sub.4, CONR.sub.1 R.sub.2 or Aryl; and R.sub.4 is NR.sub.1 R.sub.2, C.sub.1 -C.sub.8 alkyl, Aryl or C.sub.1 -C.sub.8 alkylAryl.
    Type: Grant
    Filed: June 20, 1997
    Date of Patent: August 10, 1999
    Assignee: Pharmacia & Upjohn Company
    Inventors: Arthur G. Romero, Jeffrey A. Leiby